CYP2J2 and breast cancer: In a recent cohort study investigating the association of pharmacogenetic variations to hematologic toxicity in Ethiopian breast cancer patients, we reported that patients carrying CYP2J2*7 variant alleles were associated with higher incidence of hematological toxicity (Ahmed et al., 2019).